The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I/II study of LDE225, a smoothened (Smo) antagonist, in pediatric patients with recurrent medulloblastoma (MB) or other solid tumors.
Birgit Geoerger
No relevant relationships to disclose
Isabelle Aerts
No relevant relationships to disclose
Michela Casanova
Consultant or Advisory Role - Roche
Julia C. Chisholm
No relevant relationships to disclose
Darren R Hargrave
Consultant or Advisory Role - Novartis (U)
Sarah Leary
Research Funding - Novartis
David M Ashley
No relevant relationships to disclose
Eric Bouffet
No relevant relationships to disclose
Tobey MacDonald
Consultant or Advisory Role - Novartis
Eunju Hurh
Employment or Leadership Position - Novartis
Jyotirmoy Dey
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Stacey Kalambakas
Employment or Leadership Position - Novartis
Dereck Dokyi Amakye
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Mark W. Kieran
Consultant or Advisory Role - Novartis
Research Funding - Novartis